Proof of concept trial of dronabinol in obstructive sleep apnea

Frontiers in Psychiatry

Volumn 4, Issue JAN, 2013, Pages

  Prasad, Bharati ^a   Radulovacki, Miodrag G ^a   Carley, David W ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Apnea; Clinical trial; Dronabinol; Drug treatment; OSA; Placebo controlled; Randomized

Indexed keywords

DRONABINOL;

ADULT; AGED; APNEA HYPOPNEA INDEX; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART PALPITATION; HUMAN; INCREASED APPETITE; MALE; OXIMETRY; OXYGEN SATURATION; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; SIDE EFFECT; SLEEP DISORDERED BREATHING; SOMNOLENCE;

EID: 84877721409     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00001     Document Type: Article

References (17)

1. American Sleep Disorders Association. (1992). EEG arousals: scoring rules, and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15, 173-184.
2. Carley, D. W., Pavlovic, S., Janelidze, M., and Radulovacki, M. (2002). Functional role for cannabinoids in respiratory stability during sleep. Sleep 25, 391-398.
3. Carley, D. W., and Radulovacki, M. (2008). Pharmacology of vagal afferent influences on disordered breathing during sleep. Respir. Physiol. Neurobiol. 164, 197-203.
4. Cheer, J. F., Cadogan, A.-K., Marsden, C. A., Fone, K. C. F., Kendall, D. A. (1999). Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide, and the role of cannabinoid receptors. Neuropharmacology 38, 533-541.
5. Di Marzo, V., Melck, D., Bisogno, T., and De Petrocellis, L. (1998). Endo-cannabinoids: endogenous cannabinoid receptor ligands with neuro-modulatory action. Trends Neurosci. 21, 521-528.
6. Fan, P. (1995). Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73, 907-910.
7. Fenik, P., Ogawa, H., and Veasey, S. C. (2001). Hypoglossal nerve response to 5-HT3 drugs injected into the XII nucleus, and vena cava in the rat. Sleep 24, 871-878.
8. Kimura, T., Ohta, T., Watanabe, K., Yoshimura, H., and Yamamoto, I. (1998). Anandamide, an endogenous cannabinoid recep tor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol. Pharm. Bull. 21, 224-226.
9. Kohler, M., Stoewhas, A. C., Ayers, L., Senn, O., Bloch, K. E., Russi, E. W., et al. (2011). Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 184, 1192-1199.
10. Kopczynska, B. (2007). The contribution of VR1, and CB1 receptors, and the role of the afferent vagal pathway in modelling of cardio-respiratory effects of anandamide in rats. Life Sci. 80, 1738-1745.
11. Lin, Y. S., and Lee, L. Y. (2002). Stimulation of pulmonary vagal C-fibres by anandamide inanaesthetized rats: role of vanilloid type 1 receptors. J. Physiol. 539(Pt 3), 947-955.
12. Padley, J. R., Li, Q., Pilowsky, P. M., and Goodchild, A. K. (2003). Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats. Br. J. Pharmacol. 140, 384-394.
13. Pertwee, R. G. (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411.
14. Radulovacki, M. S., Trbovic, M., and Carley, D. W. (1998). Serotonin 5-HT3-receptorantagonistGR38032F suppresses sleep apneas in rats. Sleep 21, 131-136.
15. Smith, I., Lasserson, T. J., and Wright, J. J. (2006). Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst. Rev. CD003002. doi: 10.1002/14651858
16. The Report of an American Academy of Sleep Medicine Task Force. (1999). Sleep-related breathing disorders in adults: recommendations for syndrome definition, and measurement techniques in clinical research. Sleep 22, 667-689.
17. Weaver, T. E., and Grunstein, R. R. (2008). Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc. Am. Thorac. Soc. 5, 173-178.